216 related articles for article (PubMed ID: 34674115)
1. Difelikefalin: First Approval.
Deeks ED
Drugs; 2021 Nov; 81(16):1937-1944. PubMed ID: 34674115
[TBL] [Abstract][Full Text] [Related]
2. Difelikefalin: A New κ-Opioid Receptor Agonist for the Treatment of Hemodialysis-Dependent Chronic Kidney Disease-Associated Pruritus.
Fugal J; Serpa SM
Ann Pharmacother; 2023 Apr; 57(4):480-488. PubMed ID: 35942600
[TBL] [Abstract][Full Text] [Related]
3. Intravenous difelikefalin for the treatment of hemodialysis pruritus.
Mahmoud RH; Mahmoud O; Yosipovitch G
Expert Rev Clin Immunol; 2024; 20(1):31-37. PubMed ID: 37847514
[TBL] [Abstract][Full Text] [Related]
4. Difelikefalin for pruritus associated with renal disease.
Manenti L; Fenaroli P
Drugs Today (Barc); 2022 Sep; 58(9):427-435. PubMed ID: 36102903
[TBL] [Abstract][Full Text] [Related]
5. Impact of Difelikefalin on the Health-Related Quality of Life of Haemodialysis Patients with Moderate-To-Severe Chronic Kidney Disease-Associated Pruritus: A Single-Arm Intervention Trial.
Fotheringham J; Guest J; Latus J; Lerma E; Morin I; Schaufler T; Soro M; Ständer S; Zeig S
Patient; 2024 Mar; 17(2):203-213. PubMed ID: 38196014
[TBL] [Abstract][Full Text] [Related]
6. Difelikefalin (Korsuva) for chronic kidney disease-associated pruritus.
Med Lett Drugs Ther; 2022 Feb; 64(1643):18-19. PubMed ID: 35134047
[No Abstract] [Full Text] [Related]
7. Phase 2 Trial of Difelikefalin in Notalgia Paresthetica.
Kim BS; Bissonnette R; Nograles K; Munera C; Shah N; Jebara A; Cirulli J; Goncalves J; Lebwohl M;
N Engl J Med; 2023 Feb; 388(6):511-517. PubMed ID: 36780675
[TBL] [Abstract][Full Text] [Related]
8. Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis.
Thokala P; Hnynn Si PE; Hernandez Alava M; Sasso A; Schaufler T; Soro M; Fotheringham J
Pharmacoeconomics; 2023 Apr; 41(4):457-466. PubMed ID: 36735201
[TBL] [Abstract][Full Text] [Related]
9. Difelikefalin improves itch-related sleep disruption in patients undergoing haemodialysis.
Weiner DE; Schaufler T; McCafferty K; Kalantar-Zadeh K; Germain M; Ruessmann D; Morin I; Menzaghi F; Wen W; Ständer S
Nephrol Dial Transplant; 2024 Jun; 39(7):1125-1137. PubMed ID: 37968132
[TBL] [Abstract][Full Text] [Related]
10. Difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease on hemodialysis.
Rastogi A; Fishbane S; Lerma E
Expert Rev Clin Pharmacol; 2023 May; 16(5):387-400. PubMed ID: 37010031
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus.
Yosipovitch G; Awad A; Spencer RH; Munera C; Menzaghi F
J Am Acad Dermatol; 2023 Aug; 89(2):261-268. PubMed ID: 37059302
[TBL] [Abstract][Full Text] [Related]
12. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus.
Fishbane S; Jamal A; Munera C; Wen W; Menzaghi F;
N Engl J Med; 2020 Jan; 382(3):222-232. PubMed ID: 31702883
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of difelikefalin as a treatment option for moderate-to-severe pruritus in end stage renal disease.
Lipman ZM; Yosipovitch G
Expert Opin Pharmacother; 2021 Apr; 22(5):549-555. PubMed ID: 33190563
[No Abstract] [Full Text] [Related]
14. Difelikefalin in Black/African American Hemodialysis Patients with Moderate-to-Severe Pruritus: Post hoc Analysis of KALM-1 and KALM-2.
Fishbane S; Clegg DJ; Lerma EV; Rastogi A; Budden J; Morin I; Wen W; Menzaghi F; Topf J
Am J Nephrol; 2024; 55(3):329-333. PubMed ID: 38253036
[TBL] [Abstract][Full Text] [Related]
15. Difelikefalin for Hemodialysis Patients with Pruritus in Japan.
Narita I; Tsubakihara Y; Takahashi N; Ebata T; Uchiyama T; Marumo M; Okamura S; Gejyo F;
NEJM Evid; 2023 Nov; 2(11):EVIDoa2300094. PubMed ID: 38320524
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial.
Narita I; Tsubakihara Y; Uchiyama T; Okamura S; Oya N; Takahashi N; Gejyo F;
JAMA Netw Open; 2022 May; 5(5):e2210339. PubMed ID: 35511180
[TBL] [Abstract][Full Text] [Related]
17. Safety and Effectiveness of Difelikefalin in Patients With Moderate-to-Severe Pruritus Undergoing Hemodialysis: An Open-Label, Multicenter Study.
Weiner DE; Vervloet MG; Walpen S; Schaufler T; Munera C; Menzaghi F; Wen W; Bhaduri S; Germain MJ;
Kidney Med; 2022 Oct; 4(10):100542. PubMed ID: 36185706
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of difelikefalin in the treatment of hemodialysis patients with pruritus: A meta-analysis and systematic review.
Xue G; Yuan H; Fan D; Yang Y; Ma C; Liu J; Liao R
Clin Nephrol; 2024 Apr; 101(4):155-163. PubMed ID: 38294219
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies.
Topf J; Wooldridge T; McCafferty K; Schömig M; Csiky B; Zwiech R; Wen W; Bhaduri S; Munera C; Lin R; Jebara A; Cirulli J; Menzaghi F
Kidney Med; 2022 Aug; 4(8):100512. PubMed ID: 36016762
[TBL] [Abstract][Full Text] [Related]
20. Kappa opioid agonists in the treatment of itch: just scratching the surface?
Beck TC; Wilson EM; Wilkes E; Lee LW; Norris R; Valdebran M
Itch (Phila); 2023; 8(4):. PubMed ID: 38099236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
